Sanofi Consumer Healthcare India Limited has released its unaudited financial results for the quarter ended March 31, 2026. The company reported a revenue of ₹2,292 million for the quarter, demonstrating strong operational performance. Profit for the period stood at ₹678 million. The results reflect the company’s successful product relaunch strategy and a significant recovery in export operations compared to the same period in the previous year.
Quarterly Financial Performance
For the fourth quarter ended March 31, 2026, Sanofi Consumer Healthcare India Limited reported a total revenue of ₹2,348 million, comprising ₹2,292 million from operations and ₹56 million in other income. The company achieved a profit of ₹678 million for the quarter, reflecting a steady growth trend in profitability. The total comprehensive income for the same period was also recorded at ₹678 million, with basic earnings per share at ₹29.44.
Operational Highlights
The company noted a strong rebound in business activities following the strategic product recalls implemented in 2024. The successful relaunch of key products, including Combiflam Suspension, Allegra Suspension, and Depura Kids, has contributed to a more stable domestic market presence. Consequently, domestic sales saw a growth of 15.5%, while export sales surged by 144.4% compared to the quarter ended March 31, 2025.
Strategic Outlook
Management confirmed that the company continues to operate within a single business segment, the ‘Pharmaceutical Business’. The company remains free of any subsidiaries, associates, or joint ventures as of March 31, 2026. Moving forward, the company is actively monitoring the finalization of Central and State Rules related to the new labour codes, ensuring appropriate accounting treatment and compliance in future periods.
Source: BSE
